On September 9, Quality Brands Protection Committee of China Association of Enterprises with Foreign Investment (QBPC) Pharmaceutical & Medical Device IWG held an IWG Meeting in Xiamen, which was also accessible online. Ji Ying (from Johnson & Johnson), IWG Coordinator and QBPC Vice Chair, presided over the meeting and more than 20 representatives from 10 member companies attended the event.
The meeting briefly recalled the 2nd IP Forum & 2021-2022 Top Ten Cases Sharing in Xiamen, and discussed newly promulgated Measures for the Supervision and Administration over Online Drug Sales(《药品网络销售监督管理办法》), rules concerning cross-border e-commerce drug sales and medical device infringement etc.. Xu Haifeng, Captain of the first division of the Environmental Food and Drug Protection Department of Tianjin Public Security Bureau, attended the meeting and answered the questions raised by members.
Then Ji Ying discussed the articles of The Measures for the Supervision and Administration over Online Drug Sales(《药品网络销售监督管理办法》) with the participants, especially the interpretation of the qualification of pharmaceutical online shops, drug display, third-party platform responsibilities including qualification review, information retention period and so on. They sorted out the policies, regulations, operating models and infringement points of cross-border drug sales on international e-commerce platforms. Meanwhile, they also shared their experience in dealing with low-price drugs (reflux drugs) sold on e-commerce platforms.
QBPC Internet Committee Chair Felix Zhang (from Novartis) introduced the recent exchanges and cooperation between IWG members and some e-commerce platforms in coping with reflux drugs generated by medicare fraud, covert drug sales by online drug information consulting companies, and cracking down on illegal sales of unauthorized drugs by some "overseas flagship stores" in China. He also explained the latest progress of related projects.
In addition, the participants also discussed evidence collection of patent infringement on medical devices and the illegal inflow of foreign listed drugs without approval by Chinese government. In the end, Ji Ying expressed her gratitude for the active participation of the members and looked forward to the next meeting.
